Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes.

Jennifer Goldman

Yakov M. Koen

Steven A. Rogers

Kelin Li

J Steven Leeder

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Recommended Citation

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Short Communication

Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes

Received June 9, 2016; accepted July 22, 2016

ABSTRACT

The formation of drug-protein adducts via metabolic activation and covalent binding may stimulate an immune response or may result in direct cell toxicity. Protein covalent binding is a potentially pivotal step in the development of idiosyncratic adverse drug reactions (IADRs). Trimethoprim (TMP)-sulfamethoxazole (SMX) is a combination antibiotic that commonly causes IADRs. Recent data suggest that the contribution of the TMP component of TMP-SMX to IADRs may be underappreciated. We previously demonstrated that TMP is bioactivated to chemically reactive intermediates that can be trapped in vitro by N-acetyl cysteine (NAC), and we have detected TMP-NAC adducts (i.e., mercapturic acids) in the urine of patients taking TMP-SMX. However, the occurrence and extent of TMP covalent binding to proteins was unknown. To determine the ability of TMP to form protein adducts, we incubated [14C]TMP with human liver microsomes and observed protein covalent binding that was NADPH dependent and increased with incubation time and concentration of both protein and TMP. The estimated covalent binding was 0.8 nmol Eq TMP/mg protein, which is comparable to the level of covalent binding for several other drugs that have been associated with covalent binding–induced toxicity and/or IADRs. NAC and selective inhibitors of CYP2B6 and CYP3A4 significantly reduced TMP covalent binding. These results demonstrate for the first time that TMP bioactivation can lead directly to protein adduct formation, suggesting that TMP has been overlooked as a potential contributor of TMP-SMX IADRs.

Introduction

Trimethoprim (TMP)-sulfamethoxazole (SMX) is one of the most commonly prescribed antibiotics worldwide (Van Boeckel et al., 2014). Although TMP-SMX is considered safe and efficacious, it causes a higher rate of idiosyncratic adverse drug reactions (IADRs) compared with most other drugs (Boye and Gaustad, 1991; Macy and Poon, 2009; Björnsson, 2015). SMX is implicated in TMP-SMX–associated IADRs by evidence of SMX bioactivation, protein adduct formation, and immune stimulation (Cribb and Spielberg, 1992; Cribb et al., 1997; Naishbitt et al., 2002). However, SMX alone cannot explain all IADRs to the combination drug, because TMP (when prescribed alone) has also been associated with severe IADRs and the rates of IADRs are higher for TMP-SMX than for SMX alone (Harding et al., 1975; Bergan and Skjerven, 1979; Hawkins et al., 1993; Mortimer et al., 2005).

Although the mechanisms associated with the development of many IADRs have not been fully elucidated, bioactivation of drugs to reactive intermediates that covalently bind to proteins is a generally accepted pathway that can contribute to IADR development (Zhou et al., 2005; Nakayama et al., 2009; Park et al., 2011; Björnsson, 2015). In general, drugs found to be more commonly implicated in inducing IADRs tend to exhibit higher in vitro protein binding compared with those with a lower risk profile (Takakusa et al., 2008; Nakayama et al., 2009). Thus, a critical step for understanding the mechanism of TMP-induced IADRs is to determine its potential for covalent binding to proteins after bioactivation to reactive metabolites.

Recent evidence suggests that TMP undergoes oxidative bioactivation, either by quinone imine formation or by O-demethylation followed by quinone methide formation (Lai et al., 1999; Damsten et al., 2008) (Fig. 1). These in vitro findings are consistent with our recent in vivo findings of TMP-derived mercapturic acids, such as N-acetyl cysteine (NAC) conjugates of TMP, in the urine of TMP-SMX–exposed children and demonstrate for the first time that TMP bioactivation and detoxification occurs in humans (van Haandel et al., 2014). Additional in vitro studies involving human liver microsomes (HLMs), recombinant cytochrome P450s (P450s), and specific P450 inhibitors demonstrated that CYP3A4 was the primary enzyme contributing to TMP bioactivation (Goldman et al., 2015). Although these data clearly demonstrated that TMP undergoes bioactivation in vitro and in human patients, the extent to which bioactivated TMP metabolites covalently bind to proteins remained unknown.

The main objective of this work was to characterize the extent of irreversible covalent binding of TMP to microsomal protein. [14C]-TMP was synthesized for this purpose, because radiolabeled drugs have proven to be effective in the estimation of covalent binding to cellular macromolecules. Inhibition experiments targeting specific drug-metabolizing enzymes were used to define hepatic enzyme contribution to TMP protein covalent binding, and trapping experiments with NAC and N-acetyl lysine (NAL) were performed to demonstrate protection of proteins by surrogate nucleophiles.

Materials and Methods

Materials. EDTA, glucose-6-phosphate dehydrogenase, magnesium chloride, NAC, NAL, NADP, potassium phosphate dibasic, potassium phosphate monobasic, TMP, montelukast, quinidine, sulfaphenazole, and 1-benzylimidazole were synthesized for this purpose, because radiolabeled drugs have proven to be effective in the estimation of covalent binding to cellular macromolecules. Inhibition experiments targeting specific drug-metabolizing enzymes were used to define hepatic enzyme contribution to TMP protein covalent binding, and trapping experiments with NAC and N-acetyl lysine (NAL) were performed to demonstrate protection of proteins by surrogate nucleophiles.
were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO). Benzylavpinol and thiopeta were purchased from Toronto Research Chemicals (Toronto, Canada). Ketoconazole was obtained from Research Biochemicals International (Natick, MA). Trichloroacetic acid was purchased from Fisher Scientific (Fairlawn, NJ). Pooled HLMs from 16 donors were purchased from XenoTech, LLC (Lenexa, KS). Microsomes were stored at −80°C and placed on ice prior to use, and the same lot of pooled HLMs was used for all experiments.

**[14C]-TMP Synthesis.** The synthesis of 2-[^14C]-TMP was modeled after the procedure of Hoffer et al. (1971) (Fig. 2). The modification was first verified using nonradioactive materials to give 65%–75% yields of pure TMP (confirmed by thin-layer chromatography, high-performance liquid chromatography, and high-resolution mass spectrometry) on the same scale as planned for the radiosynthesis described below. [14C]-Guanidine hydrochloride (500 µCi, approximately 50 Ci/mmol, approximately 9 µmol; Moravek Biochemicals, Brea, CA) was transferred with 1 ml MeOH into a 13-mm × 100-mm culture tube and sodium methoxide in methanol (1.0 ml, 0.5 M) was added. The reaction mixture was stirred at 70°C for 30 minutes. After the reaction mixture was cooled to room temperature, 3-anilino-2-(3,4,5-trimethoxybenzyl) acrylonitrile (48.8 mg, 150 µmol) mixture and stirred at 70°C for 16 hours. The reaction mixture was cooled to room temperature, and guanidine hydrochloride (9.55 mg, 100 µmol) in 1.0 ml methanol was added to the reaction mixture and stirred at 70°C for another 16 hours. The mixture was cooled to room temperature and transferred to a 50-ml round-bottom flask and evaporated to dryness. The residue was dissolved in 2.5% MeOH in dichloromethane (DCM) and loaded on a 4-g prepacked silica gel column. The column was washed with DCM (12 ml), 2.5% MeOH/DCM (30 ml), and 5% MeOH/DCM (30 ml) and the product was eluted with 10% MeOH/DCM, with monitoring by thin-layer chromatography, high-performance liquid chromatography, and high-resolution mass spectrometry) on the same scale as planned for the radiosynthesis described below. The residue was dissolved in 2.5% MeOH in dichloromethane (DCM) and placed on ice prior to use, and the same lot of DCM was added, with monitoring by thin-layer chromatography. The combined fraction was evaporated to dryness. The residue was dissolved in 2.5% MeOH in dichloromethane (DCM) and transferred with 1 ml MeOH into a 13-mm × 50 mm). When the mixture was transferred to a scintillation vial for storage. The specific activity was 2.9 Ci/mol, approximately 9

**Trichloroacetic acid again, 95% ethanol, 95% ethanol again, and finally ethyl acetate.**

**Fig. 1. Proposed pathway of TMP bioactivation and protein covalent binding.**

**Results and Discussion**

In the presence of an NADPH-generating system, HLMs generated measurable [14C]-TMP protein covalent binding up to 747 dpm/100 µg protein, which equates to approximately 0.8 nmol Eq bound TMP/mg protein. Covalent binding increased linearly with increasing TMP concentration, protein concentration, and incubation time (Fig. 3). For all incubations performed, nonspecific covalent binding observed in the absence of NADPH and for HLMs was subtracted to determine net NADPH-dependent covalent binding (Fig. 4).

The presence of NAC (5 mM) decreased the amount of covalent binding by 73% (P < 0.005), whereas NAL had no effect on covalent binding of TMP (Fig. 3). Net TMP covalent binding was completely abolished with the addition of 1-benzylimidazole, a potent P450 inhibitor that may affect various P450 isoforms. In addition, several isoform-specific P450 inhibitors also significantly decreased the amount of covalent binding (Fig. 5). Thiopeta (a selective CYP2B6 inhibitor) and ketoconazole (a selective CYP3A4 inhibitor) inhibited TMP covalent binding by 64% and 51%, respectively (P < 0.05). Sulfaphenazole (a selective CYP2C9 inhibitor) inhibited TMP covalent binding by 34%, but this was not significant (P = 0.10).

The results presented here demonstrate several important findings. First, TMP metabolites definitely become covalently bound to proteins when TMP is incubated with HLMs, and the amount of covalent binding and incubation conditions (TMP concentration, protein concentration, and incubation time) were determined using least-squares regression analysis. Significance was determined by Pearson’s regression analysis using a two-tailed t test with α equal to 0.05 by using GraphPad software (GraphPad Software Inc., La Jolla, CA). Effects of NAC, NAL, and the selective P450 inhibitors were determined by comparing the amount of covalent binding expressed as a percentage of the uninhibited control incubation.

**In Vitro Incubation Conditions.** Incubations (150 µl) contained HLMs (500–1500 µg microsomal protein/ml), potassium phosphate buffer (50 mM, pH 7.4), MgCl2 (3 mM), EDTA (1 mM), and [14C]-TMP (50–250 µM). The first step in setting up incubations involved transferring the required amount of [14C]-TMP into the tubes using 50 µl methanol, which was then removed by evaporation under a gentle stream of nitrogen. After adding the other components, reactions were initiated (10 U/ml). Reactions were incubated in a shaking water bath at 37°C for 120 minutes. Incubations without the addition of NADPH were performed to determine net covalent binding (Fig. 4). After all washes, the strips were air-dried and submitted to liquid scintillation counting (Wallin et al., 1981; Dansette et al., 1991).

**[14C]-TMP Covalent Binding Inhibition Experiments.** Incubations (1500 µg microsomal protein/ml, [14C]-TMP 100 µM, 120 minutes) were performed in the presence and absence of NAC (5 mM) or NAL (5 mM) to determine the extent of covalent binding inhibition and implicate the putative covalent binding site as cysteine and/or lysine. Net covalent binding was also determined in the presence and absence of selective P450 inhibitors including thiopeta (CYP2B6, 50 µM), montelukast (CYP2C8, 5 µM), sulfaphenazole (CYP2C9, 10 µM), benzylavpinol (CYP2C19, 10 µM), quinidine (CYP2D6, 5 µM), and ketoconazole (CYP3A4, 1 µM). 1-Benzylimidazole (1 mM) was used as a nonspecific P450 inhibitor. Inhibitor concentrations were approximately 30 times Ki. Inhibition experiments were performed in triplicate or quadruplicate.

**Data Analysis.** Correlation coefficients (r) between [14C]-TMP protein covalent binding and incubation conditions (TMP concentration, protein concentration, and incubation time) were determined using least-squares regression analysis. Significance was determined by Pearson’s regression analysis using a two-tailed t test with α equal to 0.05 by using GraphPad software (GraphPad Software Inc., La Jolla, CA). Effects of NAC, NAL, and the selective P450 inhibitors were determined by comparing the amount of covalent binding expressed as a percentage of the uninhibited control incubation.

**Fig. 2. Structure, synthesis, and labeling of [14C]-TMP. The black dot indicates the position of the 14C label.**
binding observed increases linearly with increases in incubation time, TMP concentration, and protein concentration. Second, the addition of 5 mM NAC significantly inhibited TMP protein covalent binding, whereas 5 mM NAL had no effect, thus implicating protein sulfhydryl groups as the likely target sites in proteins. Third, the selective inhibition of CYP2B6 or CYP3A4 significantly decreases the observed amount of TMP covalent binding.

The maximum covalent binding detected after incubations of [14C]-TMP with HLMs was 0.8 nmol Eq/mg protein. This amount of covalent binding is comparable or greater than that reported for other drugs that are known to undergo bioactivation followed by protein covalent binding and subsequent adverse drug reactions (ADRs), including benzbromarone (0.39 nmol Eq/mg protein) (Takakusa et al., 2008), acetaminophen (0.09 nmol Eq/mg protein) (Nakayama et al., 2009), and flutamide (0.18 nmol Eq/mg protein) (Nakayama et al., 2009). It has been proposed that the covalent binding of chemically reactive metabolites to cellular proteins could result in direct organ toxicity as well as the formation of neoantigens that result in immune or even autoimmune reactivity (Koen et al., 2012). Interestingly, our results demonstrate that TMP has higher covalent binding capabilities in vitro with HLM incubations than previously observed with SMX (0.003 nmol Eq/mg protein) (Nakayama et al., 2009).

Until now, the ADRs observed with TMP-SMX have been attributed solely to the SMX component (or its metabolites), but our results show that TMP undergoes metabolic activation and covalent binding at least as efficiently as SMX and several other hepatotoxic drugs (Cheng et al., 2008). Our findings support the hypothesis that TMP has the potential to contribute to IADR development in these patients exposed to TMP-SMX via the pathway of bioactivation followed by protein adduct formation.

Modest concentrations of NAC (a soft nucleophile similar to glutathione) significantly inhibited TMP covalent binding, suggesting that protein covalent binding of TMP likely occurs on cysteine residues, whereas no inhibition was observed in the presence of NAL (a hard nucleophile). The observed effect of NAC on TMP covalent binding suggests that glutathione has the ability to decrease covalent binding of
TMP metabolites to protein. In vivo, the scavenging of reactive TMP metabolites by glutathione probably serves as a protective mechanism (Haouzi et al., 2000; Jaeschke et al., 2002) as well as a route to the formation of urinary mercapturic acids. Our previous findings revealed that all TMP-exposed individuals bioactivate TMP to some extent, as shown by their urinary excretion of TMP mercapturic acids (van Haandel et al., 2014). In addition, we found a 17-fold variation in TMP mercapturate formation among individual HLM preparations used in previous phenotyping experiments when NAC was added, suggesting that variability of bioactivation and protein covalent binding likely occurs in vivo (Goldman et al., 2015). However, the occurrence and extent of TMP protein adduct formation had not been determined until now.

With the inhibition of CYP2B6 and CYP3A4, a greater than 50% net decrease in TMP covalent binding was observed. These findings are in agreement with our previous work using HLMs, individual P450 isoforms, and isoform-selective P450 inhibitors, which revealed CYP3A4 as the isoform most strongly correlated with TMP-NAC generation (Goldman et al., 2015). We also found that the CYP2B6 inhibitor thiotepa inhibited TMP-NAC formation at the highest concentration used (150 μM), even though recombinant CYP2B6 did not appear to catalyze TMP-NAC formation (Goldman et al., 2015). This could be attributable to the fact that thiotepa is also known to be a mechanism-based inactivator of CYP3A enzymes. The high interindividual variation in TMP-mercapturate formation in HLMs supplemented with NAC may lead to differences in the extent of TMP covalent binding, and this may be directly or indirectly related to the idiosyncratic development of ADRs (Ozdemir et al., 2000; Lamba et al., 2010).

In summary, based on the extent of TMP protein adduct formation observed, further investigation of the role of protein covalent binding of TMP metabolites in the generation of IADRs is clearly warranted. A better understanding of the mechanisms associated with TMP covalent binding in vivo and potential downstream immune stimulation may provide predictive insight into which individuals are at greatest risk of developing an IADR. Currently, the extent of TMP protein adduct formation in vivo, and whether patients who develop an IADR have more extensive protein adduct formation, remains unknown.

**Fig. 4.** Effect of NADPH on the covalent binding of [14C]-TMP to HLMs. Pooled HLMs were incubated under standard conditions in the absence or presence of NADPH, with [14C]-TMP (50–250 μM) at 37 ± 1°C for 120 minutes. An aliquot (100 μl) of the incubation mixture was applied to absorbent filter paper strips as outlined in the Materials and Methods. Radioactivity associated with the precipitated protein was estimated by liquid scintillation counting. A low level of apparent covalent binding was noted in those incubations without NADPH and this amount was considered background and subtracted.

**Fig. 5.** Effects of various P450 isoform-selective inhibitors on the covalent binding of [14C]-TMP to pooled HLMs as analyzed in the Materials and Methods. Each bar represents the mean and standard deviation. CVB, covalent binding.

**Table 1.** Summary of the extent of TMP protein adduct formation in vivo, and whether patients who develop an IADR have more extensive protein adduct formation remains unknown.

<table>
<thead>
<tr>
<th>Cytochrome P450 Inhibitors (μM)</th>
<th>Percent of control CVB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>100</td>
</tr>
<tr>
<td>1-Benzylimidazole (nonspecific)</td>
<td>50</td>
</tr>
<tr>
<td>Thiotepa (CYP2B6)</td>
<td>50</td>
</tr>
<tr>
<td>Montelukast (CYP2C8)</td>
<td>50</td>
</tr>
<tr>
<td>Sulphenazole (CYP2C9)</td>
<td>50</td>
</tr>
<tr>
<td>Benzylurea (CYP2C19)</td>
<td>50</td>
</tr>
<tr>
<td>Quinidine (CYP2D6)</td>
<td>50</td>
</tr>
<tr>
<td>Ketoconazole (CYP3A4)</td>
<td>50</td>
</tr>
</tbody>
</table>

**Present Address:**
JENNIFER L. GOLDMAN
YAKOV M. KOEN
STEVEN A. ROGERS
KELIN LI
JAMES S. LEEDER
ROBERT P. HANZLIK

**Authorship Contributions**
Participated in research design: Goldman, Koen, Rogers, Li, Hanzlik.
Conducted experiments: Goldman, Koen, Rogers, Li, Hanzlik.
Performed data analysis: Goldman, Koen, Hanzlik.
Wrote or contributed to the writing of the manuscript: Goldman, Koen, Leeder, Hanzlik.
References


Address correspondence to: Dr. Jennifer L. Goldman, Divisions of Pediatric Infectious Diseases and Clinical Pharmacology, Children’s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108. E-mail: jjgoldman@cmh.edu